Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes From Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

SKIN The Journal of Cutaneous Medicine
doi 10.25251/skin.1.supp.3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

National Society for Cutaneous Medicine

Related search

The Course of Chronic Plaque-Type Psoriasis in Placebo Groups of Randomized Controlled Studies

Archives of Dermatology
2004English

Patient-Reported Outcomes From Two Randomized, Double-Blind, Vehicle Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

SKIN The Journal of Cutaneous Medicine
2018English

Serlopitant for the Treatment of Chronic Pruritus: Results of a Randomized, Multicenter, Placebo-Controlled Phase 2 Clinical Trial

Journal of the American Academy of Dermatology
Dermatology
2018English

The Efficacy of Certolizumab Pegol Re-Treatment on Plaque Psoriasis Following a Blinded Treatment Break: Results From the CIMPACT Trial

SKIN The Journal of Cutaneous Medicine
2019English

Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study

SKIN The Journal of Cutaneous Medicine
2019English

Adalimumab for Nail Psoriasis: Efficacy and Safety Over 52 Weeks From a Phase‐3, Randomized, Placebo‐Controlled Trial

Journal of the European Academy of Dermatology and Venereology
DermatologyInfectious Diseases
2019English

Patient-Reported Outcomes of Multiple Myeloma Patients Treated With Panobinostat After ≥2 Lines of Therapy Based on the International Phase 3, Randomized, Double-Blind, Placebo-Controlled PANORAMA-1 Trial

British Journal of Haematology
Hematology
2018English

Adalimumab for Nail Psoriasis: Efficacy and Safety From the First 26 weeks of a Phase 3, Randomized, Placebo-Controlled Trial

Journal of the American Academy of Dermatology
Dermatology
2018English

Adalimumab for Nail Psoriasis: Efficacy and Safety From the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial

SKIN The Journal of Cutaneous Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy